Recently, complementary activity of CTLA4 and PD‐1 checkpoint inhibitors in MM treatments has been demonstrated,27 and a combination of stereotactic body RT, anti‐CTLA‐4, and anti‐PD‐1 ligands promoted tumor responses in murine B‐16 models and patients.33 This evidence concerns the gene CTLA4 and Miyoshi myopathy.